Ethical conduct is a priority for GSK and we are committed to performance with integrity. We have robust policies and compliance processes covering all our operations, including the way we reward our sales representatives, how we market our medicines and vaccines, and how we work with stakeholders.
Our compliance programmes embed the same standards across our business units in different countries. These include our Code of Conduct (PDF), which outlines how all employees should apply our Values and Behaviours, and our Global Code of Practice for Promotion and Customer Interactions (PDF), which applies to all employees involved in sales and marketing as well as third parties acting on our behalf.
All GSK employees have access to whistleblowing mechanisms that they can use to get advice and to report suspected cases of misconduct – anonymously if required.
Embedding our values in performance measurement
Living our values is one of the six expectations we use to measure employees’ performance through our global performance system. This puts the emphasis on the way employees achieve results, rather than just the results themselves. As part of this continued focus on embedding values in our performance management, in 2015 we extended our existing recoupment programme to cover approximately 1,100 senior managers globally. We have also fundamentally changed the compensation model for our sales teams to focus on patient needs.
Anti-bribery and Corruption
We have zero tolerance for bribery or corruption in any form. Our Anti-Bribery and Corruption (ABAC) programme includes risk assessments, standards and additional training for people working in high risk areas. More than 54,000 employees completed this training in 2015. We are now rolling out a new and simpler framework to engage and train third parties based on their risk profile. In our 2015 employee survey, 85% of respondents agreed that their work environment encourages ethical behaviour even in the face of pressures to meet business objectives. For more detailed information on our approach to ethical conduct and our performance in 2015 see our Responsible Business Supplement 2015 (PDF).